Table 1

Baseline and follow-up data from contacts B and D

Time pointOutcomes measured
Contact BFurther demographic information including date of birth and date of diagnosis of PD
Full screening questions according to inclusion and exclusion criteria
Medication regime and calculation of Levodopa equivalent daily dose
H&Y score
MoCA
BDI II, AS, ESS
Timed Up and Go Test
NMSS
PDSS-2
RBD-SQ
Contact D (the SPHERE house stay)MDS-UPDRS (the motor subscale will be performed on multiple occasions, once while ‘off’ medications)
PDQ-39
Symptom and activity diary
Sleep diary
Bladder diary
Medication-taking record
Sensor data from scripted activities
Sensor data from free-living
Sensor data from wearable devices provided through IXICO
Annotations of colour video dataset
Gait mat assessments
Interview with questions relating to experience of living with SPHERE technology
  • AS, Apathy Scale; BDI BDI II, Beck’s Depression Inventory II; ESS, Epworth Sleepiness Scale; H&Y, Hoehn and Yahr; MDS-UPDRS, Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale; MoCA, Montreal Cognitive Assessment; NMSS, Non-Motor Symptoms Scale for Parkinson’s disease; PD, Parkinson's disease; PDQ-39, Parkinson’s Disease Questionnaire-39; PDSS-2, Parkinson’s Disease Sleep Scale-2; RBD-SQ, REM sleep Behaviour Disorder Screening Questionnaire; SPHERE, Sensor Platform for HEalthcare in a Residential Environment.